Sight Sciences, Inc. SGHT

Company Overview

Sight Sciences, Inc. is a U.S.-based medical technology company focused on ophthalmology, with a primary emphasis on interventional glaucoma treatment and dry eye disease management. The company develops and commercializes minimally invasive technologies intended to address underlying causes of chronic eye diseases rather than relying exclusively on pharmaceutical therapies. Sight Sciences operates within the broader medical device and ophthalmic healthcare industries, serving ophthalmologists, ambulatory surgery centers, and eye care clinics.

The company’s principal revenue drivers are its interventional glaucoma products, including the OMNI Surgical System and SION Surgical Instrument, as well as its dry eye treatment platform, TearCare. Sight Sciences positions itself within the growing minimally invasive glaucoma surgery (MIGS) market and the procedural dry eye treatment segment, emphasizing physician adoption, procedural efficiency, and disease intervention earlier in the treatment continuum. Founded in 2011, the company evolved from a glaucoma-focused device developer into a broader ophthalmic platform company through internal product development and commercialization expansion.